A Breath of Fresh Air for Paroxysmal Atrial Fibrillation (PAF) patients.

More than 11.5 million patients suffer from PAF. Our patient-administered inhaled antiarrhythmic quickly and safely converts patients back to normal sinus rhythm.

Delivering Drugs Straight to the Heart via the Lungs

Approximately 20 million patients a year in the U.S. experience one or more forms of cardiac conditions. Current therapies for many such conditions are not optimal and result in poor patient quality of life, frequent ER visits and extended hospitalizations. These inadequacies therefore add a tremendous burden to the overall healthcare cost.

At InCarda, we see a better way. We see a future that includes improved quality of care for patients with cardiac conditions. We are committed to developing transformative therapies that patients can use with ease in the first moments of cardiovascular symptoms.